Eric L. Snyder, MD, PhD

Journal Article

1. Snyder EL, Saenz CC, Denicourt C, Meade BR, Cui XS, Kaplan IM, Dowdy SF (2005). Enhanced targeting and killing of tumor cells expressing the CXC chemokine receptor 4 by transducible anticancer peptides. Cancer Res, 65(23), 10646-50.
2. Wang T, Kobayashi T, Takimoto R, Denes AE, Snyder EL, el-Deiry WS, Brachmann R (2001). hADA3 is required for p53 activity. The EMBO journal, 20(22), 6404-13.
3. Dooley AL, Winslow MM, Chiang DY, Banerji S, Stransky N, Dayton TL, Snyder EL, Senna S, Whittaker CA, Bronson RT, Crowley D, Barretina J, Garraway L, Meyerson M, Jacks (2011). Nuclear factor I/B is an oncogene in small cell lung cancer. Genes & development, 25(14), 1470-5.
4. Watanabe H, Francis JM, Woo MS, Etemad B, Lin W, Fries DF, Peng S, Snyder EL, Tata PR, Izzo F, Schinzel AC, Cho J, Hammerman PS, Verhaak RG, Hahn WC, Rajagopal J, Jacks T, Meyerson (2013). Integrated cistromic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional target. Genes & development, 27(2), 197-210.
5. Guo JY, Karsli-Uzunbas G, Mathew R, Aisner SC, Kamphorst JJ, Strohecker AM, Chen G, Price S, Lu W, Teng X, Snyder E, Santanam U, Dipaola RS, Jacks T, Rabinowitz JD, White (2013). Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes & development, 27(13), 1447-61.
6. Li CM, Gocheva V, Oudin MJ, Bhutkar A, Wang SY, Date SR, Ng SR, Whittaker CA, Bronson RT, Snyder EL, Gertler FB, Jacks T (2015). Foxa2 and Cdx2 cooperate with Nkx2-1 to inhibit lung adenocarcinoma metastasis. Genes & development, 29(17), 1850-62.
7. Rzhetsky A, Dopazo J, Snyder E, Dangler CA, Ayala F (1996). Assessing dissimilarity of genes by comparing their RNAse A mismatch cleavage patterns. Genetics, 144(4), 1975-83.
8. Camolotto SA, Belova VK, Torre-Healy L, Vahrenkamp JM, Berrett KC, Conway H, Shea J, Stubben C, Moffitt R, Gertz J, Snyder E (2020). Reciprocal regulation of pancreatic ductal adenocarcinoma growth and molecular subtype by HNF4¿ and SIX1/4. Gut, 70(5), 900-914.
9. Snyder EL, Sandstrom DJ, Law K, Fiore C, Sicinska E, Brito J, Bailey D, Fletcher JA, Loda M, Rodig SJ, Dal Cin P, Fletcher C (2009). c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme. The Journal of pathology, 218(3), 292-300.
10. Sioletic S, Czaplinski J, Hu L, Fletcher JA, Fletcher CD, Wagner AJ, Loda M, Demetri GD, Sicinska ET, Snyder E (2014). c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas. The Journal of pathology, 234(2), 190-202.
11. Snyder EL, Bailey D, Shipitsin M, Polyak K, Loda (2009). Identification of CD44v6(+)/CD24- breast carcinoma cells in primary human tumors by quantum dot-conjugated antibodies. Laboratory investigation; a journal of technical methods and pathology, 89(8), 857-66.
12. Winslow MM, Dayton TL, Verhaak RG, Kim-Kiselak C, Snyder EL, Feldser DM, Hubbard DD, DuPage MJ, Whittaker CA, Hoersch S, Yoon S, Crowley D, Bronson RT, Chiang DY, Meyerson M, Jacks (2011). Suppression of lung adenocarcinoma progression by Nkx2-1. Nature, 473(7345), 101-4.
13. Ingram K, Samson SC, Zewdu R, Zitnay RG, Snyder EL, Mendoza M (2021). NKX2-1 controls lung cancer progression by inducing DUSP6 to dampen ERK activity. Oncogene, 41(2), 293-300.
14. Inoue H, Ishii H, Alder H, Snyder E, Druck T, Huebner K, Croce C (1997). Sequence of the FRA3B common fragile region: implications for the mechanism of FHIT deletion. Proceedings of the National Academy of Sciences of the United States of America, 94(26), 14584-9.
15. Yu BD, Becker-Hapak M, Snyder EL, Vooijs M, Denicourt C, Dowdy S (2003). Distinct and nonoverlapping roles for pRB and cyclin D:cyclin-dependent kinases 4/6 activity in melanocyte survival. Proceedings of the National Academy of Sciences of the United States of America, 100(25), 14881-6.
16. Bloushtain-Qimron N, Yao J, Snyder EL, Shipitsin M, Campbell LL, Mani SA, Hu M, Chen H, Ustyansky V, Antosiewicz JE, Argani P, Halushka MK, Thomson JA, Pharoah P, Porgador A, Sukumar S, Parsons R, Richardson AL, Stampfer MR, Gelman RS, Nikolskaya T, Nikolsky Y, Polyak (2008). Cell type-specific DNA methylation patterns in the human breast. Proceedings of the National Academy of Sciences of the United States of America, 105(37), 14076-81.
17. Vaira V, Fedele G, Pyne S, Fasoli E, Zadra G, Bailey D, Snyder E, Faversani A, Coggi G, Flavin R, Bosari S, Loda (2010). Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proceedings of the National Academy of Sciences of the United States of America, 107(18), 8352-6.
18. Gutierrez A, Snyder EL, Marino-Enriquez A, Zhang YX, Sioletic S, Kozakewich E, Grebliunaite R, Ou WB, Sicinska E, Raut CP, Demetri GD, Perez-Atayde AR, Wagner AJ, Fletcher JA, Fletcher CD, Look A (2011). Aberrant AKT activation drives well-differentiated liposarcoma. Proceedings of the National Academy of Sciences of the United States of America, 108(39), 16386-91.
19. Bollag B, Prins C, Snyder EL, Frisque R (2000). Purified JC virus T and T' proteins differentially interact with the retinoblastoma family of tumor suppressor proteins. Virology, 274(1), 165-78.
20. Mollaoglu G, Jones A, Wait SJ, Mukhopadhyay A, Jeong S, Arya R, Camolotto SA, Mosbruger TL, Stubben CJ, Conley CJ, Bhutkar A, Vahrenkamp JM, Berrett KC, Cessna MH, Lane TE, Witt BL, Salama ME, Gertz J, Jones KB, Snyder EL, Oliver T (2018). The Lineage-Defining Transcription Factors SOX2 and NKX2-1 Determine Lung Cancer Cell Fate and Shape the Tumor Immune Microenvironment. Immunity, 49(4), 764-779.e9.
21. Nagahara H, Vocero-Akbani AM, Snyder EL, Ho A, Latham DG, Lissy NA, Becker-Hapak M, Ezhevsky SA, Dowdy S (1998). Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nature medicine, 4(12), 1449-52.
22. Kinsey CG, Camolotto SA, Boespflug AM, Gullien KP, Foth M, Shea JE, Seipp MT, Yap JT, Burrell LD, Lum DH, Whisenant JR, Gilcrease GW, Cavlieri CC, Rehbein KM, Cutler SL, Affolter KE, Welm AL, Welm BE, Scaife CL, Snyder EL and McMahon M (2019). Protective autophagy elicited by RAF-> MEK -> ERK inhibition suggests a treatment strategy for RAS-driven cancers. Nature medicine, 25(4), 620-627.
23. Snyder EL, Watanabe H, Magendantz M, Hoersch S, Chen TA, Wang DG, Crowley D, Whittaker CA, Meyerson M, Kimura S, Jacks (2013). Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma. Molecular cell, 50(2), 185-99.
24. Snyder EL, Meade BR, Dowdy S (2003). Anti-cancer protein transduction strategies: reconstitution of p27 tumor suppressor function. Journal of controlled release, 91(1-2), 45-51.
25. Gidekel Friedlander SY, Chu GC, Snyder EL, Girnius N, Dibelius G, Crowley D, Vasile E, DePinho RA, Jacks (2009). Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. Cancer cell, 16(5), 379-89.
26. Zhang YX, Sicinska E, Czaplinski JT, Remillard SP, Moss S, Wang Y, Brain C, Loo A, Snyder EL, Demetri GD, Kim S, Kung AL, Wagner A (2014). Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo. Molecular cancer therapeutics, 13(9), 2184-93.
27. Caswell DR, Chuang CH, Ma RK, Winters IP, Snyder EL, Winslow M (2018). Tumor Suppressor Activity of Selenbp1, a Direct Nkx2-1 Target, in Lung Adenocarcinoma. Molecular cancer research, 16(11), 1737-1749.
28. Snyder EL, Meade BR, Saenz CC, Dowdy S (2004). Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide. PLoS biology, 2(2), E36.
29. Camolotto SA, Pattabiraman S, Mosbruger TL, Jones A, Belova VK, Orstad G, Streiff M, Salmond L, Stubben C, Kaestner KH, Snyder E (2018). FoxA1 and FoxA2 drive gastric differentiation and suppress squamous identity in NKX2-1-negative lung cancer. eLife, 7,
30. Orstad G, Fort G, Parnell TJ, Jones A, Stubben C, Lohman B, Gillis KL, Orellana W, Tariq R, Klingbeil O, Kaestner K, Vakoc CR, Spike BT, Snyder E (2022). FoxA1 and FoxA2 control growth and cellular identity in NKX2-1-positive lung adenocarcinoma. Developmental cell, 57(15), 1866-1882.e10.
31. Gillis K, Orellana WA, Wilson E, Parnell TJ, Fort G, Fang P, Essel Dadzie H, Murphy BM, Zhang X, Snyder E (2024). FoxA1/2-dependent epigenomic reprogramming drives lineage switching in lung adenocarcinoma. Developmental cell, 60(3), 472-489.e8.
32. Ghazi PC, O'Toole KT, Srinivas Boggaram S, Scherzer MT, Silvis MR, Zhang Y, Bogdan M, Smith BD, Lozano G, Flynn DL, Snyder EL, Kinsey CG, McMahon (2024). Inhibition of ULK1/2 and KRAS(G12C) controls tumor growth in preclinical models of lung cancer. eLife, 13,
33. Zewdu R, Mehrabad EM, Ingram K, Fang P, Gillis KL, Camolotto SA, Orstad G, Jones A, Mendoza MC, Spike BT, Snyder E (2021). An NKX2-1/ERK/WNT feedback loop modulates gastric identity and response to targeted therapy in lung adenocarcinoma. eLife, 10,
34. Fang P, Wilson ER, Larsen SN, Orellana WA, Hall MA, Stubben C, Kabir AH, Affolter K, Moffitt RA, Zhang X, Snyder E (2025). Differential control of growth and identity by HNF4¿ isoforms in pancreatic ductal adenocarcinoma. Molecular cancer research, 23(11), 936-952.
35. Fort G, Arnold H, Camolotto SA, O'Toole K, Tariq R, Waters A, Gillis K, Snyder E (2025). Opposing lineage specifiers induce a protumor hybrid identity state in lung adenocarcinoma. Genes & development,
36. Cai L, Wu F, Zhou Q, Gao Y, Yao B, DeBerardinis RJ, Acquaah-Mensah GK, Aidinis V, Beane JE, Biswal S, Chen T, Concepcion-Crisol CP, Grüner BM, Jia D, Jones RA, Kurie JM, Lee MG, Lindahl P, Lissanu Y, Lorz C, MacPherson D, Martinelli R, Mazur PK, Mazzilli SA, Mii S, Moll HP, Moorehead RA, Morrisey EE, Ng SR, Oser MG, Pandiri AR, Powell CA, Ramadori G, Santos M, Snyder EL, Sotillo R, Su KY, Taki T, Taparra K, Tran PT, Xia Y, van Veen JE, Winslow MM, Xiao G, Rudin CM, Oliver TG, Xie Y, Minna J (2025). The Lung Cancer Autochthonous Model Gene Expression Database Enables Cross-Study Comparisons of the Transcriptomic Landscapes Across Mouse Models. Cancer research, 85(10), 1769-1783.
37. O'Toole KT, Martinez A, Murphy B, Proveyeka A, Fort G, Al-Sudani F, Boggaram S, Paine EL, Baral D, Andersen JL, Parkman G, Snyder EL, Judson-Torres R, McMahon (2025). Characterization of the BRAF interactome identifies BRAF (V600E) TP53 interaction in melanoma. bioRxiv,
38. Essel Dadzie H, Green YS, Camolotto S, Gumbleton M, Maeda Y, Spike BT, Snyder E (2025). HNF4¿ controls growth, identity and response to KRAS inhibition of invasive mucinous adenocarcinoma of the lung. bioRxiv,
39. Stuart WD, Ito M, Baldauf IF, Fukazawa T, Yamatsuji T, Tsuchiya T, Watanabe H, Okada M, Snyder EL, Mino-Kenudson M, Guo M, Maeda (2024). Patho-transcriptomic analysis of invasive mucinous adenocarcinoma of the lung (IMA): comparison with lung adenocarcinoma with signet ring cell features (SRCC). bioRxiv,
40. Liu B, Stuart WD, Fink-Baldauf IM, Boscolo E, Mino-Kenudson M, Snyder EL, Maeda (2025). PBAE-PEG/Lipid Nanoparticle Delivery of RNA for the Creation of Genetically Engineered Lung Cancer Mouse Models. Nano letters, 25(51), 17578-17583.
41. Gillis K, Orellana WA, Snyder E (2026). Protocol to extract and sort GFP-tagged nuclei from lung adenocarcinoma tissue in genetically engineered mouse models. STAR protocols, 7(1), 104328.

Review

1. Farago AF, Snyder EL, Jacks (2012). SnapShot: Lung cancer models. Cell, 149(1), 246-246.
2. Snyder EL, Dowdy S (2004). Cell penetrating peptides in drug delivery. Pharmaceutical research, 21(A), 389-393.
3. Snyder EL, Dowdy S (2001). Protein/peptide transduction domains: potential to deliver large DNA molecules into cells. Current opinion in molecular therapeutics, 3(2), 147-52.
4. Snyder EL, Dowdy S (2005). Recent advances in the use of protein transduction domains for the delivery of peptides, proteins and nucleic acids in vivo. Expert opinion on drug delivery, 2(1), 43-51.
5. Camolotto SA, Belova VK, Snyder EL (2018). The role of lineage specifiers in pancreatic ductal adenocarcinoma. Journal of gastrointestinal oncology, 9(6), 1005-1013.

Editorial

1. Gumbleton M, Snyder E (2023). TTF-1 and immune checkpoint therapy in non-small cell lung cancer. Translational lung cancer research, 12(3), 398-400.

Other

1. Kinsey CG, Camolotto SA, Boespflug AM, Guillen KP, Foth M, Truong A, Schuman SS, Shea JE, Seipp MT, Yap JT, Burrell LD, Lum DH, Whisenant JR, Gilcrease GW 3rd, Cavalieri CC, Rehbein KM, Cutler SL, Affolter KE, Welm AL, Welm BE, Scaife CL, Snyder EL, McMahon (2025). Author Correction: Protective autophagy elicited by RAF'MEK'ERK inhibition suggests a treatment strategy for RAS-driven cancers. Nature medicine, 31(6), 2069.

Huntsman Cancer Institute News

• Discovery Innovations Fall 2025